Peter C. Richardson

Insider Reports History

Location
Valencia, CA
Signature
/s/ Mark Tyndall, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Peter C. Richardson:

Company Role Class Num Shares Value Price $ Report Date Ownership
Mallinckrodt plc EVP & Chief Scientific Officer Restricted Stock Units 27,357 31 Jul 2025 Direct
Mallinckrodt plc EVP & Chief Scientific Officer Ordinary Shares 3,419 $37.50 01 Jan 2025 Direct
ANTARES PHARMA, INC. EVP, Research and Development and Chief Medical Officer Common Stock 0 $5.60 24 May 2022 Direct
ANTARES PHARMA, INC. EVP, Research and Development and Chief Medical Officer Stock Option (right to buy) 0 24 May 2022 Direct

Insider Reports Filed by Peter C. Richardson

Symbol Company Period Transactions Value $ Form Type Role Filing Time
Mallinckrodt plc 31 Jul 2025 1 $0 4 EVP & Chief Scientific Officer 04 Aug 2025, 20:48
NONE Mallinckrodt plc 01 Jan 2025 2 $0 4 EVP & Chief Scientific Officer 02 Jan 2025, 17:02
NONE Mallinckrodt plc 02 Feb 2024 1 $0 4 EVP & Chief Scientific Officer 06 Feb 2024, 16:27
MNKTQ Mallinckrodt plc 14 Nov 2023 1 $0 4 EVP & Chief Scientific Officer 16 Nov 2023, 16:14
MNK Mallinckrodt plc 30 Jun 2023 1 $0 4 EVP & Chief Scientific Officer 05 Jul 2023, 18:17
MNK Mallinckrodt plc 03 Apr 2023 1 $0 4 EVP & Chief Scientific Officer 05 Apr 2023, 19:05
MNK Mallinckrodt plc 02 Feb 2023 1 $0 4 EVP & Chief Scientific Officer 03 Feb 2023, 12:31
MNK Mallinckrodt plc 12 Jan 2023 0 $0 3 EVP & Chief Scientific Officer 20 Jan 2023, 08:32
ATRS ANTARES PHARMA, INC. 24 May 2022 4 -$283,433 4 EVP, Research and Development and Chief Medical Officer 26 May 2022, 17:27
ATRS ANTARES PHARMA, INC. 10 Jun 2021 2 +$160,000 4 EVP, R&D Chief Medical Officer 14 Jun 2021, 18:25